Sarcoma  >>  gemcitabine  >>  Phase 3
Welcome,         Profile    Billing    Logout  

14 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gemcitabine / Generic mfg.
NCT00142571: Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

Completed
3
120
US
Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center, Connective Tissue Oncology Society, M.D. Anderson Cancer Center, Massachusetts General Hospital, Mayo Clinic, University of Michigan Rogel Cancer Center
Sarcoma, Soft Tissue
 
09/07
NCT01012297: Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Terminated
3
107
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Docetaxel, RP56976, Taxotere, Taxotere Injection Concentrate, Filgrastim, Filgrastim XM02, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Neulasta, SD-01, SD-01 sustained duration G-CSF, Placebo, placebo therapy, PLCB, sham therapy
National Cancer Institute (NCI), NRG Oncology
Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
09/15
09/15
2009-014907-29: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas

Ongoing
3
250
Europe
Doxorubicin, Docetaxel, Gemcitabine,
University College London
Locally advanced unresectable or metastatic soft tissue sarcoma.
 
 
2010-023484-17: Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared de tronco en adultos: un enfoque integrador que incluye tratamiento con medicamentos antitumorales estándar comparado con tratamientos específicos para las diferentes variedades histológicas como primer tratamiento.

Ongoing
3
250
Europe
epirrubicina, ifosfamida, Gemcitabina, Docetaxel, Etoposido, FARMIBLASTINA, Dacarbazina, epirubicin, ifosfamide, gemcitabine, docetaksel, etoposide, dacarbazine, epirubicin, ifosfamide, gemcitabine, docetaksel, etoposide, dacarbazine
ITALIAN SARCOMA GROUP, Grupo Español de Investigación en Sarcomas, Italian Sarcoma Group, , Grupo Español de Investigación en Sarcomas, NHS (diagnostic and therapeutic procedures), Eurosarc, funded by project/grant FP7
High risk localized soft tissue sarcomas typical of the adult
 
 
2012-002852-17: A Phase III Randomised Trial of Gemcitabine plus Docetaxel followed by Doxorubicin versus observation for uterus-limited, high grade uterine leiomyosarcoma

Completed
3
216
Europe
Gemcitabine, Doxorubicin, Powder for solution for infusion, Concentrate for solution for infusion, Powder and solvent for solution for infusion, Gemzar (Gemcitabine 200 mg), Gemzar (Gemcitabine 1000 mg), Taxotere® (Docetaxel), Doxorubicin (Adriamycin)
EORTC, EORTC
Patients with high risk uterine LMS, FIGO stage I (confined to corpus +/- cervix)., High risk uterine leiomyosarcoma, Diseases [C] - Cancer [C04]
 
 
NCT02049905 / 2013-004103-40: Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Completed
3
433
Europe, Canada, US, RoW
Aldoxorubicin, INNO-206, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide), Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide
ImmunityBio, Inc.
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
05/17
05/17
GOG study , NCT01533207: Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

Terminated
3
38
Europe, US, RoW
Clinical Observation, observation, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Filgrastim, FILGRASTIM, LICENSE HOLDER UNSPECIFIED, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Pegfilgrastim Biosimilar HSP-130, SD-01, SD-01 sustained duration G-CSF
Gynecologic Oncology Group, National Cancer Institute (NCI)
Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma
06/18
02/19
NCT06370871: Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Not yet recruiting
3
263
NA
Brigimadlin, BI 907828, Ezabenlimab, BI 754091, Gemcitabine, Docetaxel
Boehringer Ingelheim
Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS)
07/26
10/28
ISG-STS-1001, NCT01710176: Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

Active, not recruiting
3
550
Europe
epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3), gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8), trabectedin 1.3 mg/m2, high-dose ifosfamide 14 g/m2, given in in 14 days, etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3), gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
Italian Sarcoma Group, French Sarcoma Group, Grupo Espanol de Investigacion en Sarcomas
Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults
06/24
06/24
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
jRCTs031180003: JCOG1306:Randomized phase II/III study of adjuvant chemotherapy with Adriamycin+Ifosfamide vs Gemcitabine+Docetaxel for high-grade soft tissue sarcoma ( AI vs GD for STS RPII/III )

Completed
2/3
140
Japan
ifosfamide - Generic mfg., gemcitabine - Generic mfg., docetaxel - Generic mfg.
Okayama University Hospital
Soft tissue sarcoma
 
 
2014-000259-99: A comparison of four widely used chemotherapy regimens for the treatment of Ewing sarcoma, a type of bone cancer, to see which is most effective and/or has the fewest side effects.

Ongoing
2/3
400
Europe
Cyclophosphamide, Topotecan, Irinotecan, Temozolomide, Gemcitabine, Docetaxel, Ifosfamide, Cyclophosphamide, Topotecan, Irinotecan, Temozolomide, Gemcitabine, Docetaxel, Ifosfamide, Infusion, Capsule, hard, , Cyclophosphamide, HYCAMTIN, CAMPTO, Temodal, GEMZAR, TAXOTERE, Ifosfamide
University of Birmingham, UNIVERSITY OF BIRMINGHAM, European Commission, German Cancer Aid
Recurrent and refractory Ewing sarcoma, Ewing sarcoma, a type of bone cancer, that has either grown during initial treatment or has grown after the end of treatment., Diseases [C] - Cancer [C04]
 
 
NCT02099396: A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma

Unknown status
2/3
100
NA
Docetaxel+lobaplatin, Gemcitabine+lobaplatin
China Association of Osteosarcoma Chemotherapy
Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma
06/16
 
2019-002662-12: A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy Etude de phase II/III, randomisée, multicentrique évaluant le TSR-042 (anti-PD-1 mAb) associé au Niraparib versus le Niraparib seul comparé à la chimiothérapie chez des patientes atteintes d’un carcinosarcome métastasique ou en récidive de l’ovaire ou de l’endomètre après une chimiothérapie de première intention

Not yet recruiting
2/3
196
Europe
NIRAPARIB, DOSTARLIMAB, TSR-042, Capsule, Powder for solution for infusion, Concentrate for solution for infusion, Solution for infusion, Solution for solution for infusion, NIRAPARIB, GEMCITABINE, PACLITAXEL, DOXORUBICINE LIPOSOMALE PEGYLEE, TOPOTECAN, DOXORUBICINE IV
ARCAGY-GINECO, TESARO
metastatic or recurrent endometrial or ovarian carcinosarcoma, metastatic or recurrent endometrial or ovarian carcinosarcoma, Diseases [C] - Cancer [C04]
 
 

Download Options